BV has also been studied combined with the PD-1 inhibitor nivolumab in several trials, including the ACCRU RU0515051 phase II trial in older or chemotherapy-ineligible cHL patients [57], the phase II trial (BV+nivolumab post-HSCT) in high-risk R/R cHL [58], the CheckMate 436 phase I/II trial in primary mediastinal large B-cell lymphoma (PMBL) [59], and the SGN35-015 phase II trial in older patients with advanced cHL [44]. This evidence concerns the gene RPL17 and classic Hodgkin lymphoma.